Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInventory AverageInvested CapitalMarket Capitalization

RedHill Biopharma (RDHL) EBIT Margin: 2012-2023

Historic EBIT Margin for RedHill Biopharma (RDHL) over the last 11 years, with Jun 2023 value amounting to 2,992.87%.

  • RedHill Biopharma's EBIT Margin rose 322408.00% to 2,992.87% in Q2 2023 from the same period last year, while for Jun 2023 it was -122.98%, marking a year-over-year increase of 7662.00%. This contributed to the annual value of -181.69% for FY2024, which is 37513.00% down from last year.
  • RedHill Biopharma's EBIT Margin amounted to 2,992.87% in Q2 2023, which was up 470.40% from -808.00% recorded in Q1 2023.
  • In the past 5 years, RedHill Biopharma's EBIT Margin registered a high of 2,992.87% during Q2 2023, and its lowest value of -808.00% during Q1 2023.
  • Moreover, its 3-year median value for EBIT Margin was 60.50% (2021), whereas its average is 117.23%.
  • In the last 5 years, RedHill Biopharma's EBIT Margin crashed by 152,314bps in 2021 and then skyrocketed by 322,408bps in 2023.
  • Over the past 5 years, RedHill Biopharma's EBIT Margin (Quarterly) stood at 739.87% in 2019, then slumped by 63,736bps to 102.51% in 2020, then tumbled by 74,395bps to -641.43% in 2021, then skyrocketed by 4,962bps to -591.81% in 2022, then spiked by 322,408bps to 2,992.87% in 2023.
  • Its last three reported values are 2,992.87% in Q2 2023, -808.00% for Q1 2023, and -591.81% during Q4 2022.